Company: ZRCN
Filing Date: 2025-09-10
Form Type: 10-K
Source: 0001641172-25-027037
Chunk: 133

Company: ZRCN Inc.
Filing Date: 2025-09-10
Form: 10-K
Item: Item 1
Chunk 133
---
 provide such guidance. Our guidance may not always be accurate. We may also choose to withdraw
guidance, or lower guidance in future periods. If, in the future, our results of operations
for a particular period do not meet our guidance or the expectations of investment analysts, we reduce our guidance for future periods,
or we withdraw guidance, the market price of our common stock could decline significantly.

If
we are unable to maintain effective internal controls over financial reporting in the future, the accuracy and timeliness of our financial
reporting may be adversely affected, which could have a material adverse effect on our financial condition and the trading
price of our common stock.

As
a public company, we are required to design and maintain proper and effective internal controls over financial reporting and to report
any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act of 2002 may require that we evaluate and determine
the effectiveness of our internal controls over financial reporting and provide a management report on the internal controls over financial
reporting, which must be attested to by our independent registered public accounting firm. If we become unable to maintain effective
internal controls over financial reporting, our ability to record, process and report financial information timely and accurately could
be adversely affected.

Risks
Related to our Common Stock

We
may conduct offerings of our equity securities in the future, in which case an investor’s proportionate interest may become diluted.

If
we issue additional common stock shares or securities convertible into our common stock, your percentage interest in the Company could
become diluted.

During
any future financing, when common stock is issued in return for capital investment, the price per share could be lower than that paid
by our current shareholders.

The
sale or availability of substantial amounts of our common stock could adversely affect their market price.

Should
we become a publicly listed company, sales of substantial amounts of our common stock in the public market, or the perception that these
sales could occur, could adversely affect the market price of our common stock and could materially impair our ability to raise capital
through equity offerings in the future. As of the date of this report, we have 10,332,425 shares of common stock issued and outstanding.
We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder or the
availability of these securities for future sale will have on the market price of our common stock.

16

We
have never declared or paid